The insulin-like growth factor I receptor: a key to tumor growth?

The insulin-like growth factor I receptor (IGF-IR) belongs to the family of transmembrane tyrosine kinase receptors, like the receptors for platelet-derived growth factor, the epidermal growth factor, insulin, and others. Genetic evidence has shown that the IGF-IR is required for optimal growth in vitro and in vivo. Even more important, however, have been recent findings from several laboratories clearly showing that the IGF-IR is an absolute requirement for the establishment and maintenance of the transformed phenotype, both in vivo and in vitro and in several cell types. These findings indicate that the IGF-IR plays a central role in the mechanism of transformation and, as such, could be a preferred target for therapeutic interventions.

[1]  K. Hagino-Yamagishi,et al.  [Oncogene]. , 2019, Gan to kagaku ryoho. Cancer & chemotherapy.

[2]  C. Kitanaka,et al.  Apoptosis in cancer. , 1996, Human cell.

[3]  D. Coppola,et al.  Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. , 1994, Cancer research.

[4]  D. Fisher.  Apoptosis in cancer therapy: Crossing the threshold , 1994, Cell.

[5]  D. Coppola,et al.  A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor , 1994, Molecular and cellular biology.

[6]  D. Hanahan,et al.  A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis , 1994, Nature.

[7]  C. Rogler,et al.  Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. , 1994, The Journal of biological chemistry.

[8]  D. Coppola,et al.  Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. , 1994, Cancer research.

[9]  S. Asa,et al.  Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[10]  M. Rubini,et al.  The role of the IGF‐I receptor in the growth and transformation of mammalian cells , 1994, Cell proliferation.

[11]  C. Kahn,et al.  The insulin signaling system. , 1994, The Journal of biological chemistry.

[12]  L. Wang,et al.  Distinctive effects of the carboxyl-terminal sequence of the insulin-like growth factor I receptor on its signaling functions , 1993, Journal of virology.

[13]  J. Baker,et al.  Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r) , 1993, Cell.

[14]  Elizabeth J. Robertson,et al.  Role of insulin-like growth factors in embryonic and postnatal growth , 1993, Cell.

[15]  C. Crews,et al.  Extracellular signals and reversible protein phosphorylation: What to Mek of it all , 1993, Cell.

[16]  M. White,et al.  IRS-1 is a common element in insulin and insulin-like growth factor-I signaling to the phosphatidylinositol 3'-kinase. , 1993, Endocrinology.

[17]  A. Ullrich,et al.  Roles of insulinlike growth factor 1 (IGF-1) and the IGF-1 receptor in epidermal growth factor-stimulated growth of 3T3 cells , 1992, Molecular and cellular biology.

[18]  M. Tykocinski,et al.  Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[19]  V. Macaulay,et al.  Insulin-like growth factors and cancer. , 1992, British Journal of Cancer.

[20]  M. Willingham,et al.  EGF-R antisense RNA blocks expression of the epidermal growth factor receptor and suppresses the transforming phenotype of a human carcinoma cell line. , 1992, The Journal of biological chemistry.

[21]  W. Rutter,et al.  Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation , 1990, Molecular and cellular biology.

[22]  C. Osborne,et al.  Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. , 1989, Cancer research.

[23]  C Collins,et al.  Insulin‐like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. , 1986, The EMBO journal.

[24]  C. Stiles,et al.  Dual control of cell growth by somatomedins and platelet-derived growth factor. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[25]  F. Bresciani,et al.  Cell kinetics and growth of squamous cell carcinomas in man. , 1974, Cancer research.

[26]  M. Tykocinski,et al.  Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. , 1993, Science.

[27]  R. Baserga,et al.  Cell cycle and growth control. , 1993, Critical reviews in eukaryotic gene expression.

[28]  B. Bengtsson.  Acromegaly and Neoplasia , 1993, The Journal of pediatric endocrinology.

[29]  R. Baserga.  The double life of the IGF-1 receptor. , 1992, Receptor.